



# Centers for Disease Control and Prevention (CDC) Immunization Safety Office (ISO) Update

Advisory Commission on Childhood Vaccines (ACCV) meeting  
December 2, 2021

Jonathan Duffy, MD, MPH  
Immunization Safety Office  
Centers for Disease Control and Prevention

**COVID-19 vaccines**

# COVID-19 ACIP Vaccine Recommendations

- The Advisory Committee on Immunization Practices (ACIP) currently has recommendations for the use of three different COVID-19 vaccines
  - Pfizer-BioNTech COVID-19 Vaccine
  - Moderna COVID-19 Vaccine
  - Janssen COVID-19 Vaccine
- Recommendations available at:  
<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html>

# ACIP held additional meetings to discuss topics related to COVID-19 vaccines

- September 22-23, 2021
- October 21, 2021
- November 2, 2021
- November 19, 2021

# Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines

- In the United States, three COVID-19 vaccines are approved or authorized for primary vaccination against COVID-19.
- The Advisory Committee on Immunization Practices issued recommendations for an additional primary mRNA COVID-19 vaccine dose for immunocompromised persons and a COVID-19 vaccine booster dose in eligible groups.

# Everyone Ages 18 and Older Should Get a Booster Shot

IF YOU RECEIVED

Pfizer-BioNTech or Moderna

---

**Who should get a booster:**

Everyone 18 years or older

**When to get a booster:**

At least 6 months after completing your primary COVID-19 vaccination series.

**Which booster should you get?**

[Any of the COVID-19 vaccines](#) authorized in the United States.

IF YOU RECEIVED

Johnson & Johnson's Janssen

---

**Who should get a booster:**

Everyone 18 years or older

**When to get a booster:**

At least 2 months after completing your primary COVID-19 vaccination.

**Which booster should you get?**

[Any of the COVID-19 vaccines](#) authorized in the United States.

Source: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html>

# Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years

- On October 29, 2021, the Food and Drug Administration granted Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine for children aged 5–11 years.
- On November 2, 2021, after a systematic review of available data, the Advisory Committee on Immunization Practices made an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in children aged 5–11 years in the United States for prevention of COVID-19.
- The Pfizer-BioNTech COVID-19 vaccine has high efficacy (>90%) against COVID-19 in children aged 5–11 years, and benefits outweigh risks for vaccination. Vaccination is important to protect children against COVID-19 and reduce community transmission of SARS-CoV-2.

Source: <https://www.cdc.gov/mmwr/volumes/70/wr/mm7045e1.htm>

# COVID-19 vaccine safety publications

- Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA 2021 Sept 3.
- Spontaneous Abortion Following COVID-19 Vaccination During Pregnancy. JAMA 2021 Sep 8.
- Receipt of mRNA COVID-19 Vaccines and Risk of Spontaneous Abortion. N Engl J Med. 2021 Sept 8.
- Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12-September 19, 2021. MMWR Morb Mortal Wkly Rep. epub 2021 Sep 28.

Available at: <https://www.cdc.gov/vaccinesafety/research/publications/index.html>



## COVID-19 vaccine safety publications, continued

- Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system. Vaccine 2021 Oct 16
- Safety Monitoring of mRNA Vaccines Administered During the Initial 6 months of the U.S. COVID-19 Vaccination Program: Reports to Vaccine Adverse Events Reporting System (VAERS) and v-safe. medRxiv – the preprint server for health sciences 2021 Oct 28
- COVID-19 Vaccination and Non-COVID-19 Mortality Risk — Seven Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021. MMWR Morb Mortal Wkly Rep. epub 2021 Oct 22.

Available at: <https://www.cdc.gov/vaccinesafety/research/publications/index.html>

# COVID-19 Vaccinations in the United States

- As of November 28, 2021
- People fully vaccinated: 196.2 million
- People received a booster dose: 37.5 million

Source: CDC COVID Data Tracker: <https://covid.cdc.gov/covid-data-tracker/#vaccinations>

# **Advisory Committee on Immunization Practices (ACIP)**

September, October, and November 2021 meetings other topics

# Tick-borne Encephalitis (TBE) Vaccine

- The Food and Drug Administration approved a TBE vaccine (manufactured by Pfizer as TICOVAC) on August 13, 2021
- ACIP TBE Vaccine Work Group was formed in September 2020 to review use of TBE vaccine in U.S. adults and children traveling abroad
- Planned ACIP vote on vaccine recommendations in February 2022

# Zoster Vaccine

- ACIP voted for the following recommendation:
  - Two doses of recombinant zoster vaccine are recommended for the prevention of herpes zoster and its complications in adults aged  $\geq 19$  years who are or will be immunodeficient or immunosuppressed due to disease or therapy.

# Pneumococcal Vaccines

- ACIP voted for the following two recommendations:
  - Adults 65 years of age or older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either PCV20 or PCV15). If PCV15 is used, this should be followed by a dose of PPSV23.
  - Adults aged 19 years of age or older with certain underlying medical conditions or other risk factors who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either PCV20 or PCV15). If PCV15 is used, this should be followed by a dose of PPSV23.

# Influenza Vaccines

- There were two presentations:
  - Phase II safety and immunogenicity study of the coadministration of Fluzone<sup>®</sup> HighDose Quadrivalent Influenza Vaccine and a third dose of mRNA-1273 COVID-19 vaccine (Moderna)
  - Cell culture-based inactivated influenza vaccine (IIV4) now FDA approved for ages  $\geq 6$  months
    - Five IIV4s are now approved for this age group

# Hepatitis B Vaccines

- ACIP voted for the following recommendations:
  - The ACIP recommends the following groups should receive hepatitis B vaccines
    - Adults 19 through 59 years
    - Adults 60 years and older with risk factors for hepatitis B infection
  - The ACIP recommends the following groups may receive hepatitis B vaccines
    - Adults 60 years and older without known risk factors for hepatitis B infection



# Orthopoxviruses Vaccines

- The genus *Orthopoxvirus* contains a number of species, such as smallpox and monkeypox.
- ACIP voted for five recommendations for the use of the JYNNEOS<sup>®</sup> vaccine for persons who are at risk for occupational exposure
  - laboratory personnel and for designated response team members
  - healthcare personnel who administer ACAM2000 or care for patients infected with replication competent orthopoxviruses

# Ebola vaccine

- ACIP voted for two recommendations for the use of the rVSVΔG-ZEBOV-GP vaccine
  - Pre-exposure vaccination with rVSVΔG-ZEBOV-GP vaccine is recommended for healthcare personnel involved in the care and transport of suspect or confirmed Ebola virus disease patients at Special Pathogens Treatment Centers
  - Pre-exposure vaccination with rVSVΔG-ZEBOV-GP vaccine is recommended for laboratorians and support staff at Laboratory Response Network (LRN) facilities that handle specimens that may contain replication competent Ebola virus (species *Zaire ebolavirus*) in the United States

# Thank You

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

